Lawsuit Targets Cord Blood Registry Over Misleading Claims
AUSTIN, TX & PHOENIX, AZ – The attorneys general of Texas and Arizona have jointly filed lawsuits against Cord Blood Registry (CBR), one of the nation's largest private cord blood banking services, alleging that the company engaged in deceptive advertising practices to profit from the anxieties and hopes of expectant parents. The complaints, filed on Tuesday, October 24, 2023, contend that CBR overstated the potential medical benefits and likelihood of future use for privately stored umbilical cord stem cells, leading thousands of families to invest in a service with limited current application.
Texas Attorney General Elena Rodriguez stated in a press conference that CBR's marketing materials created a false sense of urgency and necessity, preying on parents' desires to ensure their children's future health. “Choosing to bank your child’s cord blood is a significant financial and emotional decision,” said Rodriguez. “Our investigation found that Cord Blood Registry consistently overpromised the medical utility of these cells, implying they were a guaranteed 'biological insurance policy' against a vast array of future illnesses, many of which lack proven treatments using autologous cord blood.”
Similarly, Arizona Attorney General Mark Chen emphasized the financial burden placed on families. “Parents are already facing considerable expenses with a new baby. To then be misled into paying thousands of dollars for a service that is, for most, highly unlikely to be utilized, is unacceptable,” Chen added. The lawsuits seek civil penalties, restitution for affected consumers, and injunctions to prevent CBR from continuing the alleged deceptive practices.
The Nature of the Alleged Deception
At the heart of the lawsuits are claims that CBR's advertising campaigns, disseminated through various channels including online ads, brochures in doctors' offices, and parenting expos, painted an overly optimistic picture of cord blood stem cell applications. The attorneys general allege that CBR frequently highlighted experimental treatments and potential future breakthroughs as if they were established therapies, blurring the lines between research and clinical reality.
Specifically, the complaints cite instances where CBR allegedly suggested that privately banked cord blood could readily treat conditions like cerebral palsy, autism, and Alzheimer's disease, despite these applications largely remaining in early clinical trials or being unproven. Critics argue that such marketing tactics leverage the emotional vulnerability of new parents, who are often seeking every possible advantage for their child's well-being.
Private cord blood banking typically involves an initial collection and processing fee, ranging from $2,000 to $3,000, followed by annual storage fees that can vary from $150 to $200. Over 18 years, this can amount to total costs exceeding $5,000, often for a resource that has a very low probability of being used by the donor child or a family member.
Understanding Cord Blood Banking and Its Realities
Umbilical cord blood contains hematopoietic stem cells, which can differentiate into various blood cell types. These cells have been successfully used for decades in treating certain blood cancers, genetic disorders, and immune system deficiencies, primarily in allogeneic transplants (from a donor to a recipient).
However, the utility of *autologous* (self-donated) cord blood for a child's own future health is far more limited. According to the American Academy of Pediatrics (AAP), the likelihood of a child needing their own stored cord blood is extremely low, estimated to be between 1 in 2,700 and 1 in 200,000. For many conditions, if a child develops a genetic disorder, their own cord blood may carry the same genetic defect, making it unsuitable for treatment.
“While cord blood stem cells hold immense promise for future therapies, it’s crucial to distinguish between what is currently proven and what is still speculative research,” explained Dr. Anya Sharma, Director of Regenerative Medicine Research at the Global Institute for Stem Cell Research. “Private banks often capitalize on this grey area, creating a perception of immediate, broad-spectrum utility that simply isn't supported by the current body of medical evidence. For many conditions, an allogeneic match from a public bank or an unrelated donor registry is more likely to be used if a transplant is needed.”
Public vs. Private Banking: A Key Distinction
The lawsuits also highlight the distinction between private and public cord blood banking. Public banks allow parents to donate cord blood for altruistic use by anyone who needs a match, free of charge to the donor family. These public banks play a critical role in supporting the global stem cell transplant registry and advancing research. The AAP, among other medical organizations, generally recommends donation to public banks over private banking for healthy infants, unless there is a strong family history of a treatable genetic condition.
The attorneys general argue that CBR's marketing often downplayed or omitted information about public banking options, further pushing parents towards their fee-based private service.
What's Next for CBR?
Cord Blood Registry, headquartered in Tucson, Arizona, has yet to issue a comprehensive public statement regarding the specific allegations. However, in past instances of scrutiny, companies in the cord blood banking industry have often defended their practices by emphasizing their commitment to scientific advancement and providing a valuable service for families seeking to preserve biological resources. The lawsuits are expected to proceed through the state court systems, with potential for lengthy legal battles. This case underscores a growing push by consumer protection agencies to ensure transparency in health-related services, particularly those marketed to vulnerable populations like expectant and new parents.
